Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 3/20 | 0.86 |
| ▸ | PCMT1 | P22061 | 3/20 | 0.86 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.86 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.86 |
| ▸ | NSD3 | Q9BZ95 | 2/20 | 0.86 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.86 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.86 |
| ▸ | PNMT | P11086 | 1/20 | 0.86 |
| ▸ | KDR | P35968 | 1/20 | 0.86 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.86 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.86 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.86 |
| ▸ | PRMT7 | Q9NVM4 | 1/20 | 0.86 |
| ▸ | AMD1 | P17707 | 6/20 | 0.75 |
| ▸ | FASN | P49327 | 2/20 | 0.59 |
| ▸ | NNMT | P40261 | 2/20 | 0.57 |
| ▸ | NSD2 | O96028 | 2/20 | 0.54 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.54 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.54 |
| ▸ | TRDMT1 | O14717 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ademetionine SCHEMBL30034534 | 1.00 | CARM1 (0.86) | CARM1PCMT1PRMT5PRMT1NSD3 | |
| Ademetionine SCHEMBL25176 | 0.93 | CARM1 (1.00) | CARM1PCMT1PRMT5PRMT1NSD3 | |
| Ademetionine SCHEMBL1300198 | 0.93 | CARM1 (1.00) | CARM1PCMT1PRMT5PRMT1NSD3 | |
| Ademetionine SCHEMBL29355793 | 0.93 | CARM1 (1.00) | CARM1PCMT1PRMT5PRMT1NSD3 | |
| Ademetionine SCHEMBL1300205 | 0.93 | CARM1 (1.00) | CARM1PCMT1PRMT5PRMT1NSD3 | |
| Ademetionine SCHEMBL4747876 | 0.92 | CARM1 (0.98) | CARM1PCMT1PRMT5PRMT1NSD3 | |
| Ademetionine SCHEMBL1980696 | 0.92 | CARM1 (0.98) | CARM1PCMT1PRMT5PRMT1NSD3 | |
| Ademetionine SCHEMBL5465751 | 0.92 | CARM1 (0.88) | CARM1PCMT1PRMT5PRMT1NSD3 | |
| Ademetionine SCHEMBL5463109 | 0.90 | CARM1 (0.85) | CARM1PCMT1PRMT5PRMT1NSD3 | |
| Ademetionine SCHEMBL3685223 | 0.89 | CARM1 (0.83) | CARM1PCMT1PRMT5PRMT1NSD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240316089-A1 | COMBINATIONS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | KetaMed MSO, LLC | 2024-09-26 | — | — | US | claimed |
| EP-3071191-B1 | SLOW-RELEASE SOLID ORAL COMPOSITIONS | GNOSIS SPA (IT) | 2022-01-05 | — | — | EP | claimed |
| WO-2021212995-A1 | ANTI-AGEING COMPOSITION, DRUG AND HEALTHCARE PRODUCT COMPRISING SAME, AND APPLICATION THEREFOR | 百瑞全球有限公司 (VG) | 2021-10-28 | — | — | WO | claimed |
| CN-113521090-A | Anti-aging composition, medicine and health product containing anti-aging composition, and application of anti-aging composition | 百瑞全球有限公司 | 2021-10-22 | — | — | CN | claimed |
| US-10702482-B2 | Slow-release solid oral compositions | GNOSIS SPA (IT) | 2020-07-07 | — | — | US | claimed |
| CN-105764493-B | Sustained release solid oral compositions | 灵知股份公司 | 2020-02-21 | — | — | CN | claimed |
| US-20160287519-A1 | SLOW-RELEASE SOLID ORAL COMPOSITIONS | GNOSIS SPA (IT) | 2016-10-06 | — | — | US | claimed |
| WO-2024197234-A1 | COMBINATIONS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | KetaMed MSO, LLC (US) | 2024-09-26 | — | — | WO | disclosed |
| US-20240316089-A1 | COMBINATIONS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | KetaMed MSO, LLC | 2024-09-26 | — | — | US | disclosed |
| CN-115039845-A | Feed additive for improving weight and slaughtering performance of laying hens as well as preparation method and application of feed additive | 北京君德同创生物技术股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-114099456-A | Capsule containing S-adenosylmethionine and preparation method and application thereof | 郑州大学 | 2022-03-01 | — | — | CN | disclosed |
| EP-3071191-B1 | SLOW-RELEASE SOLID ORAL COMPOSITIONS | GNOSIS SPA (IT) | 2022-01-05 | — | — | EP | disclosed |
| WO-2021212995-A1 | ANTI-AGEING COMPOSITION, DRUG AND HEALTHCARE PRODUCT COMPRISING SAME, AND APPLICATION THEREFOR | 百瑞全球有限公司 (VG) | 2021-10-28 | — | — | WO | disclosed |
| US-20100055218-A1 | NOVEL COMPOSITIONS | DSM IP ASSETS B.V. (NL) | 2010-03-04 | — | — | US | disclosed |
| US-20100056463-A1 | NOVEL COMPOSITIONS | DSM IP ASSETS B.V. (NL) | 2010-03-04 | — | — | US | disclosed |
| EP-2049134-A2 | COMPOSITIONS COMPRISING ROSEHIP AND OTHER ACTIVE AGENTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | DSMIP Assets B.V. (NL) | 2009-04-22 | — | — | EP | disclosed |
| EP-2040696-A2 | COMPOSITIONS AND USE THEREOF FOR THE TREATMENT, CO-TREATMENT OR PREVENTION OF INFLAMMATORY DISORDERS | DSMIP Assets B.V. (NL) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008006581-A2 | COMPOSITIONS AND USE THEREOF FOR THE TREATMENT, CO-TREATMENT OR PREVENTION OF IMFLAMMATORY DISORDERS | DSM IP ASSETS B.V. (NL) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008006582-A1 | COMPOSITIONS COMPRISING MAGNOLOL OR HONOKIOL AND OTHER ACTIVE AGENTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | DSM IP ASSETS B.V. (NL) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008006589-A2 | COMPOSITIONS COMPRISING ROSEHIP AND OTHER ACTIVE AGENTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | DSM IP ASSETS B.V. (NL) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316089-A1 | COMBINATIONS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | GRIN3A, GRIN2A, GRIN2B | CARM1 909/4885PCMT1 416/4885PRMT5 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.